Evidence map›Paper›PMID 36293938›Full record

Trial reportInternational journal of environmental research and public health2022

Efficacy and Safety of Cytisine in Combination with a Community Pharmacists' Counselling for Smoking Cessation in Thailand: A Randomized Double-Blinded Placebo-Controlled Trial.

Pum Phusahat, Piyameth Dilokthornsakul, Watchara Boonsawat, Uraiwan Zaeoue, Nadthatida Hansuri, Nirachara Tawinkan, Ampornpan Theeranut, Sunee Lertsinudom

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Observational
  3. Review
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Pum PhusahatDivision of Pharmacy, Somdej Phra Yupparat Sa Kaeo Hospital, Sa Kaeo 27000, Thailand.
Piyameth DilokthornsakulCenter for Medical and Health Technology Assessment (CM-HTA), Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand.
Watchara BoonsawatSrinagarind Hospital, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.ORCID 0000-0003-0143-2609
Uraiwan ZaeoueSrinagarind Hospital, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.
Nadthatida HansuriCommunity Pharmacy, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand.
Nirachara TawinkanCommunity Pharmacy, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand.ORCID 0000-0002-1523-7188
Ampornpan TheeranutFaculty of Nursing, Khon Kaen University, Khon Kaen 40002, Thailand.
Sunee LertsinudomDivision of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand.
Khon Kaen University · THChiang Mai University · TH

Funding

the Government Pharmaceutical Organization, Thailand 4/2561
6 · The paper itself

Abstract

backgroundCytisine is a prospective pharmacological alternative for community pharmacy smoking cessation services. However, it has not yet been licensed because of a lack of efficacy and safety information in Thailand.

objectiveThe aim of this study was to evaluate the efficacy of cytisine in combination with community pharmacists' counselling on smoking cessation in a community pharmacy in ThailandDesign. Setting, participants, and interventions: A double-blinded randomized placebo-controlled trials was carried out. Participants aged >18 years old who smoked >10 tobaccos/day were randomly assigned to receive cytisine or placebo and five sessions of counselling by a community pharmacist. The primary outcome was a continuous abstinence rate (CAR) at week 48. The CAR was also measured at weeks 2, 4, 12, and 24. Adverse events were monitored.

resultsA total of 132 participants were included, with 67 receiving cytisine and 65 receiving a placebo. Approximately 95% of participants were male. The CARs were determined to be 14.93% and 6.15% for cytisine and placebo, respectively, at week 48. The relative risk (RR) was 2.41 (95% confidence interval (CI); 0.80-7.35,

conclusionCytisine, when combined with community pharmacists' counselling, did not statistically improve the CAR at week 48, although it did improve the CAR at weeks 2, 4, and 12. Adverse events of cytisine were common and non-serious (registration number: TCTR20180312001).

Indexed as

Smoking CessationAdolescentBenzazepinesCounselingFemaleHumansMaleNicotinic AgonistsPharmacistsProspective StudiesQuinolizidine AlkaloidsSmokingThailandVareniclineBenzazepinescytisineNicotinic AgonistsQuinolizidine AlkaloidsVareniclinecommunity pharmacistcytisineefficacysafetysmoking cessation

Identifiers

PMID36293938
PMCPMC9603285
OpenAlexW4306381811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.